The inhibition of kallikrein-bradykinin pathway may be useful in the reduction of allergic reactions during honeybee venom immunotherapy

Iranian Journal of Medical Hypotheses and Ideas

Volumn 3, Issue 1, 2009, Pages

  Mingomataj, Ervin Ç ^a,b,c   Bakiri, Alketa ^b  

^a Mother Theresa School of Medicine   (Albania)

^b UNIVERSITY OF TIRANA   (Albania)

^c NONE   (Albania)

Author keywords

Bradykinin antagonists; Hereditary angioedema; Honeybee venom immunotherapy; Kallikreinbradykinin pathway; Systemic anaphylactic reactions

Indexed keywords

ACETIC ACID; ADRENALIN; AMINOCAPROIC ACID; ANGIOTENSINOGEN; ANTIHISTAMINIC AGENT; APROTININ; BEE VENOM; BERINERT P; BRADYKININ; BRADYKININ ANTAGONIST; CAPTOPRIL; CINRYZE; COMPLEMENT COMPONENT C1S INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; ENALAPRIL; GLUCOCORTICOID; HYMENOPTERA VENOM; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR; MELITTIN; NPC 18884; PLACEBO; RENIN; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ABDOMINAL DISEASE; ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; COMPLEMENT CLASSICAL PATHWAY; DESENSITIZATION; ENZYME ACTIVATION; EXTRAVASATION; HONEYBEE; HUMAN; HYMENOPTERA; IMMUNOTHERAPY; NONHUMAN; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WASP;

EID: 77953457125     PISSN: 17359104     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ruëff F, Przybilla B. [Venomimmunotherapy. Side effects and efficacy of treatment]. Hautarzt 2008; 59: 200-5. [in German]
2. Bousquet J, Müller UR, Dreborg S, Jarisch R, Malling HJ, Mosbech H, Urbanek R, Youlten L. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology. Allergy 1987; 42: 401-13.
3. Ruëff F, Przybilla B. Venom immunotherapy: adverse reactions and treatment failure. Curr Opin Allergy Clin Immunol 2004; 4: 307-11.
4. Sánchez-Morillas L, Reaño Martos M, Rodríguez Mosquera M, Iglesias Cadarso A, Domínguez Lázaro AR. [Safety of rush immunotherapy with Hymenoptera venom]. Allergol Immunopathol (Madr) 2005; 33: 224-7. [in Spanish]
5. Gorska L, Chelminska M, Kuziemski K, Skrzypski M, Niedoszytko M, Damps-Konstanska I, Szymanowska A, Siemińska A, Wajda B, Drozdowska A, Jutel M, Jassem E. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Int Arch Allergy Immunol 2008; 147: 241-5.
6. Roy SR, Sigmon JR, Olivier J, Moffitt JE, Brown DA, Marshall GD. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2007; 99: 82-6.
7. Wenzel J, Meissner-Kraemer M, Bauer R, Bieber T, Gerdsen R. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy 2003; 58: 1176-9.
8. Przybilla B, Ruëff F. [Desensitization of allergy to hymenoptera venoms]. Wien Med Wochenschr 1999; 149: 421-8. [in German]
9. Mingomataj E, Priftanji A, Qirko E, Dinh QT, Fischer A, Peiser C, Groneberg DA. Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms. BMC Dermatol 2002; 2: 11.
10. Mingomataj EÇ, Ohri D, Dhimitri V, Priftanji A, Qirko E, Pani L, Fischer TC, Dinh QT, Peiser C, Fischer A, Groneberg DA. Hymenoptera sting anaphylactic reactions in the Mediterranean population of Albania. J Invest Allergol Clin Immunol 2003; 13: 272-7.
11. Berchtold E, Maibach R, Müller U. Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin Exp Allergy 1992; 22: 59-65.
12. Müller UR, Jutel M, Reimers A, Zumkehr J, Huber C, Kriegel C, Steiner U, Haeberli G, Akdis M, Helbling A, Schnyder B, Blaser K, Akdis C. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol 2008; 122: 1001-7.
13. Binder M, Fierlbeck G, King T, Valent P, Bühring HJ. Individual hymenoptera venom compounds induce upregulation of the basophil activation marker ectonucleotide pyrophosphatase/phosphodiesterase 3 (CD203c) in sensitized patients. Int Arch Allergy Immunol 2002; 129: 160-8.
14. Nishimura K, Alhenc-Gelas F, White A, Erdös EG. Activation of membrane-bound kallikrein and renin in the kidney. Proc Natl Acad Sci U S A 1980; 77: 4975-8.
15. Lata J, Specjalski K, Kolaczkowska M, Chelmińska M, Niedoszytko M, Jassem E. [Side effects of specific immunotherapy in patients with hymenoptera venom allergy]. Pneumonol Alergol Pol 2005; 73: 260-3. [in Polish]
16. Mingomataj EÇ. Favorable hymenoptera sting reactions during childhood may have enabled transmission of responsible allergic genotype into generations. Med Hypotheses 2006; 67: 327-32.
17. Hermann K, Ring J. Association between the renin angiotensin system and anaphylaxis. Adv Exp Med Biol 1995; 377: 299-309.
18. Hermann K, von Tschirschnitz M, Ebner von Eschenbach C, Ring J. Histamine, tryptase, norepinephrine, angiotensinogen, angiotensin-converting enzyme, angiotensin I and II in plasma of patients with hymenoptera venom anaphylaxis. Int Arch Allergy Immunol 1994; 104: 379-84.
19. Hermann K, Ring J. The renin angiotensin system and hymenoptera venom anaphylaxis. Clin Exp Allergy 1993; 23: 762-9.
20. Hermann K, Ring J. The renin-angiotensin system in patients with repeated anaphylactic reactions during hymenoptera venom hyposensitization and sting challenge. Int Arch Allergy Immunol 1997; 112: 251-6.
21. Rohit, Rao C, Krishna G. Effects of captopril and losartan on thermal and chemical induced pain in mice. Indian J Physiol Pharmacol 2006; 50: 169-74.
22. Finegold I. Issues in stinging insect allergy immunotherapy: a review. Curr Opin Allergy Clin Immunol 2008; 8: 343-7.
23. Merk HF. [Angioedema]. Hautarzt 2007; 58: 1041-5. [in German]
24. Frank MM. Hereditary angioedema. J Allergy Clin Immunol 2008; 121(2 Suppl): S398-401.
25. Ebo DG, Stevens WJ. Hereditary angioneurotic edema: review of the literature. Acta Clin Belg 2000; 55: 22-9.
26. Frank MM, Jiang H. New therapies for hereditary angioedema: disease outlook changes dramatically. J Allergy Clin Immunol 2008; 121: 272-80.
27. Neuman I, Ishay JS, Creter D. Hyperreactivity to bee stings: reevaluation. Ann Allergy 1983; 50: 410-2.
28. Beierwaltes WH, Carretero OA. Nonprostanoid endothelium-derived factors inhibit renin release. Hypertension 1992; 19(2 Suppl): II68-73.
29. Lopes P, Couture R. Localization of bradykinin-like immunoreactivity in the rat spinal cord: effects of capsaicin, melittin, dorsal rhizotomy and peripheral axotomy. Neuroscience 1997; 78: 481-97.
30. Cicardi M, Bergamaschini L, Cugno M, Beretta A, Zingale LC, Colombo M, Agostoni A. Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology 1998; 199: 366-76.
31. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002; 109: 195-209.
32. Bueno L, Fioramonti J. Effects of inflammatory mediators on gut sensitivity. Can J Gastroenterol 1999; 13 (Suppl A): 42A-46A.
33. Julia V, Mezzasalma T, Buéno L. Influence of bradykinin in gastrointestinal disorders and visceral pain induced by acute or chronic inflammation in rats. Dig Dis Sci 1995; 40: 1913-21.
34. Khasar SG, Miao JP, Jänig W, Levine JD. Modulation of bradykinin-induced mechanical hyperalgesia in the rat by activity in abdominal vagal afferents. Eur J Neurosci 1998; 10: 435-44.
35. Featherstone RL, Parry JE, Church MK. The effects of a kinin antagonist on changes in lung function and plasma extravasation into the airways following challenge of sensitized guinea-pigs. Clin Exp Allergy 1996; 26: 235-40.
36. Geppetti P, Bertrand C, Ricciardolo FL, Nadel JA. New aspects on the role of kinins in neurogenic inflammation. Can J Physiol Pharmacol 1995; 73: 843-7.
37. Samadfam R, Teixeira C, Bkaily G, Sirois P, de Brum-Fernandes A, D'Orleans-Juste P. Contribution of B(2) receptors for bradykinin in Arthus reaction-induced plasma extravasation in wild-type or B(2) transgenic knockout mice. Br J Pharmacol 2000; 129: 1732-8.
38. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity to foods, drugs, and insects in 2007. J Allergy Clin Immunol 2008; 121: 1351-8.
39. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy 2007; 62: 842-56.
40. de Campos RO, Alves RV, Ferreira J, Kyle DJ, Chakravarty S, Mavunkel BJ, Calixto JB. Oral antinociception and oedema inhibition produced by NPC 18884, a non-peptidic bradykinin B2 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 278-86.
41. Krieter DH, Grude M, Lemke HD, Fink E, Bönner G, Schölkens BA, Schulz E, Müller GA. Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin. Kidney Int 1998; 53: 1026-35.
42. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3: 311-7.
43. Reimers A, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000; 55: 484-8.
44. Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101(6 Pt 1): 747-54.